Traumatic degloving wounds can result in significant soft-tissue defects, leaving exposed neurovascular and vital structures that are not amenable to immediate flap coverage because of associated life-threatening injuries, wound contamination, and/or unknown zone of injury. The need for acute limb revascularization further complicates the reconstruction because of the need to maintain patency of the bypass graft for limb salvage. An ideal temporary coverage option would maintain the viability of the critical neurovascular structures by preventing desiccation, disruption of the anastomosis, and/or thrombosis of the bypass graft while allowing for serial debridement to remove wound contamination and allow for the full declaration of the soft tissues. Alloderm (LifeCell Corporation, Branchburg, N.J.) is a Food and Drug Administration--approved, acellular dermal matrix that does not incite a significant immune response; so it can easily be removed if needed.^[@R1]^ Alloderm has been previously described for temporary or permanent soft-tissue coverage.^[@R1]--[@R6]^ We describe 2 cases where the acellular dermal matrix was used as temporary coverage of exposed arterial bypass graft until definitive coverage.

CASE PRESENTATIONS
==================

Case 1
------

A 37-year-old man presented after an all-terrain vehicle crash, with absent left radial and ulnar pulses and soft-tissue degloving at the left antebrachial fossa. He had near transection of the left brachial artery and underwent revascularization with reverse saphenous vein graft through the traumatic wound (Fig. [1](#F1){ref-type="fig"}A). A negative-pressure dressing was placed initially, but he had a loss of the distal pulses from compression of the graft. Alloderm (LifeCell Corporation) was secured to the wound edges as a temporary dressing (Fig. [1](#F1){ref-type="fig"}B). He underwent serial debridement 3 days later with median nerve neuroplasty with Axogen wrap (AxoGen, Inc, Alachua, Fla.). Definitive coverage was performed 1 week later with lateral arm flap. There were no postoperative complications. He had no functional deficits or compromise of his bypass graft at 6 months.

![Exposed vascular bypass graft with inability to place negative pressure wound therapy. A, Left antebrachial fossa of case 1 patient immediately after brachial artery bypass graft, defect size 6 × 10 cm^2^. B, Temporary wound coverage using Alloderm.](gox-8-e2965-g001){#F1}

Case 2
------

A 32-year-old woman presented after a motor vehicle rollover with absent left radial and ulnar pulses and soft-tissue degloving at the left antebrachial fossa. She had transection of the left brachial artery and underwent revascularization with reverse saphenous vein graft to the radial artery. She had an associated ulnar nerve transection, partial median nerve transection, and open distal humerus fracture (Fig. [2](#F2){ref-type="fig"}A). Alloderm was used to cover this critical wound (Fig. [2](#F2){ref-type="fig"}B). She returned to the operating room 2 days later for thrombosis of the bypass and underwent thrombectomy of the bypass, median and ulnar nerve reconstruction with sural nerve grafts, open reduction internal fixation of the left humerus fracture, and temporary coverage with Alloderm. She had rethrombosis of the bypass the following day for which it was revised. The Alloderm was elevated and used to access the wound until she underwent definitive coverage 8 days later with a 2-stage thoracoabdominal flap. There was no further compromise of the vascular graft.

![Exposed vascular bypass graft and hardware. A, Left antebrachial fossa; case 2 patient immediately after brachial artery bypass graft, median and ulnar nerve reconstruction, and open reduction internal fixation of the left humerus fracture, defect size 12 × 20 cm^2^. B, Temporary wound coverage using Alloderm.](gox-8-e2965-g002){#F2}

DISCUSSION
==========

The ideal dressing for the temporary coverage of bypass grafts is unknown. Calligaro et al^[@R7]^ described their experience with local wound care and delayed secondary closure for infected lower-extremity arterial grafts. They had a complication rate of 28%, with 1 death from anastomotic hemorrhage and 4 graft losses from nonhealing wounds, graft thrombosis, or recurrent infection. Dosluoglu et al^[@R8]^ used vacuum-assisted closure to preserve infected and exposed vascular grafts. There were 2 failures of vacuum-assisted therapy, 1 anastomotic disruption, and 1 recurrence of infection. The application of vacuum-assisted therapy in patient 1 was aborted because of loss of distal pulses from compression of the bypass graft; hence, we did not attempt this in patient 2.

Acellular dermal matrix has been applied as temporary coverage or definitive reconstruction in the traumatic or oncologic setting, where immediate reconstruction had to be delayed.^[@R1],[@R2]^ Bastidas et al^[@R2]^ used Alloderm for temporary coverage of critical neurovascular structures. They found that the underlying neurovascular structures were intact without neurovascular or tendon desiccation or necrosis. The Alloderm was easily removed, and the wound bed remained moist with the development of healthy granulation tissue. However, they did not report using it on bypass grafts. Carlson et al^[@R3]^ described a case of a healthy male who had sustained multiple bite wounds from a domestic zebra to his left upper extremity with arterial injury needing emergent revascularization using a vein bypass graft. Alloderm was used to cover only the distal 1.5 cm of bypass graft later when it became exposed. Integra was ultimately used to cover the wound. It is not clear whether they left Alloderm or removed it.

In our study, the acellular dermal matrix was successfully used as temporary coverage between serial debridement's overexposed vascular bypass grafts. It helped prevent exposure of the bypass graft without adversely affecting it or the wound bed. The acellular dermal matrix itself was covered using bacitracin and xeroform daily dressing changes. Our experience supports the use of the acellular dermal matrix to provide temporary coverage of vital structures until definitive reconstruction can be completed.
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